What is Perfuze?
Founded in 2018 and headquartered in Galway, Ireland, Perfuze is dedicated to enhancing the treatment of ischemic strokes. The company's core innovation lies in its advanced catheter technology, engineered to improve vessel access and the efficacy of clot removal during thrombectomy. This focus addresses a critical unmet need in the medtech industry for more effective and repeatable stroke intervention methods, aiming to improve patient outcomes.
How much funding has Perfuze raised?
Perfuze has raised a total of $51.9M across 3 funding rounds:
Angel/Seed
$2.4M
Series A
$25.7M
Unspecified
$23.8M
Angel/Seed (2019): $2.4M, investors not publicly disclosed
Series A (2022): $25.7M led by LSP, SV Health Investors, and Seroba Life Sciences Management
Unspecified (2025): $23.8M supported by EQT, Earlybird, SV Health Investors, and Seroba
Key Investors in Perfuze
EQT
EQT Group is a purpose-driven global investment organization operating across private capital, infrastructure, real estate, growth equity, and venture capital strategies. They apply a thematic investment approach, targeting high-quality companies in sectors such as healthcare and technology.
Earlybird
Earlybird is a venture capital investor focused on European technology innovators, investing in technology, medical, and other related sectors. Founded in 1997, they support early-stage ventures.
SV Health Investors
SV Health Investors is a specialist investment firm backing innovative health care and life science companies, providing capital, sector expertise, and active support from early growth through scale and value creation.
What's next for Perfuze?
The recent major strategic investment signals a pivotal growth phase for Perfuze, likely enabling the company to accelerate product development, scale manufacturing, and expand its market reach. This infusion of capital, following previous funding rounds, positions Perfuze to further solidify its presence in the competitive stroke treatment landscape and bring its innovative solutions to a wider patient population. The company's trajectory suggests a strong emphasis on clinical validation and commercialization.
See full Perfuze company page
